To the Editor: Dr Nalluri and colleagues1 studied the risk of VTE in patients treated with bevacizumab. The results of the meta-analysis suggested that overall risk for both all-grade and high-grade VTE was increased in patients treated with bevacizumab. The effect was found to be dose-independent. For individual cancer types, all-grade VTE risk was only significant for renal cell carcinoma; high-grade VTE risk was significantly increased only in patients with colorectal cancer.
Kilickap S, Arslan C. Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients. JAMA. 2009;301(14):1434-1436. doi:10.1001/jama.2009.441